276 related articles for article (PubMed ID: 32257944)
21. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
Wu Z; Chen Q; Qu L; Li M; Wang L; Mir MC; Carbonara U; Pandolfo SD; Black PC; Paul AK; Di Lorenzo G; Porpiglia F; Mari A; Necchi A; Rouprêt M; Psutka SP; Autorino R
Eur Urol; 2022 Apr; 81(4):414-425. PubMed ID: 35101302
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
Front Oncol; 2022; 12():934093. PubMed ID: 35912183
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis.
Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Lee EQ; Aizer AA; Guenette JP; Huang RY
Korean J Radiol; 2021 Apr; 22(4):584-595. PubMed ID: 33289357
[TBL] [Abstract][Full Text] [Related]
24. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
Gu L; Khadaroo PA; Su H; Kong L; Chen L; Wang X; Li X; Zhu H; Zhong X; Pan J; Chen M
BMC Cancer; 2019 Jun; 19(1):559. PubMed ID: 31182049
[TBL] [Abstract][Full Text] [Related]
25. The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.
Ma K; Lu Y; Jiang S; Tang J; Li X; Zhang Y
Front Pharmacol; 2018; 9():1430. PubMed ID: 30618738
[No Abstract] [Full Text] [Related]
26. The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.
Peng M; Li X; Lei G; Weng YM; Hu MX; Song QB
Onco Targets Ther; 2018; 11():7369-7383. PubMed ID: 30425525
[TBL] [Abstract][Full Text] [Related]
27. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Bishay K; Tandon P; Bourassa-Blanchette S; Laurie SA; McCurdy JD
Curr Oncol; 2020 Oct; 27(5):e486-e494. PubMed ID: 33173388
[TBL] [Abstract][Full Text] [Related]
28. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.
Wang DY; Ye F; Zhao S; Johnson DB
Oncoimmunology; 2017; 6(10):e1344805. PubMed ID: 29123955
[No Abstract] [Full Text] [Related]
29. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis.
Sha CM; Lehrer EJ; Hwang C; Trifiletti DM; Mackley HB; Drabick JJ; Zaorsky NG
Radiother Oncol; 2020 Oct; 151():141-148. PubMed ID: 32717359
[TBL] [Abstract][Full Text] [Related]
30. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review.
Machado AP; Ratliff H; Abdelwahab A; Vohra MH; Kuang A; Shatila M; Khan MA; Shafi MA; Thomas AS; Philpott J; Alhalabi O; Wang Y
J Cancer; 2023; 14(16):2956-2963. PubMed ID: 37859810
[No Abstract] [Full Text] [Related]
31. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
32. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
33. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
Liu T; Jin B; Chen J; Wang H; Lin S; Dang J; Li G
Ther Adv Med Oncol; 2020; 12():1758835920940927. PubMed ID: 32774474
[TBL] [Abstract][Full Text] [Related]
34. Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis.
Mi Z; Zhang Y; Feng Z; Liu J; Wu J; Tan H; Ma X; Liu Z; Rong P
Artif Cells Nanomed Biotechnol; 2022 Dec; 50(1):301-309. PubMed ID: 36217590
[TBL] [Abstract][Full Text] [Related]
35. Treatment-related adverse events and response rate to immune checkpoint inhibition.
Li Y; Wang Z; Guo T; Liu S; Feng C
J Int Med Res; 2020 Mar; 48(3):300060519886454. PubMed ID: 31777292
[TBL] [Abstract][Full Text] [Related]
36. Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients.
Kovalenko I; Lynn Ng W; Geng Y; Wang Y; Msaouel P; Bhatia S; Grivas P; Benkhadra R; Alhalabi O
Front Oncol; 2023; 13():1238517. PubMed ID: 38239644
[TBL] [Abstract][Full Text] [Related]
37. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis.
Guzman-Prado Y; Ben Shimol J; Samson O
Cancer Immunol Immunother; 2021 Jan; 70(1):89-100. PubMed ID: 32648164
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis.
Wu K; Yi M; Qin S; Chu Q; Zheng X; Wu K
Exp Hematol Oncol; 2019; 8():26. PubMed ID: 31673481
[TBL] [Abstract][Full Text] [Related]
39. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis.
Chen J; Li S; Yao Q; Du N; Fu X; Lou Y; Wang M; Mao F; Mao D; Khadaroo PA; Tang Y
World J Surg Oncol; 2020 Jul; 18(1):150. PubMed ID: 32620130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
